Odylia Therapeutics

Odylia accelerates therapeutic development for rare diseases. By prioritizing safe and effective treatments regardless of number of patients, we are improving access to care for the rare disease patients who need them. By integrating scientific knowledge, operational drug development experience, and technological innovation, Odylia offers tangible support and hope for improved health with the goal of impacting current and future generations. In the United States, 1 in 10 people have a rare disease and 50% of them are children. 95% of rare diseases do not have a single FDA approved drug treatment. This is not acceptable. Odylia works hand-in-hand with patient advocacy groups to demystify the ... read more Odylia accelerates therapeutic development for rare diseases. By prioritizing safe and effective treatments regardless of number of patients, we are improving access to care for the rare disease patients who need them. By integrating scientific knowledge, operational drug development experience, and technological innovation, Odylia offers tangible support and hope for improved health with the goal of impacting current and future generations. In the United States, 1 in 10 people have a rare disease and 50% of them are children. 95% of rare diseases do not have a single FDA approved drug treatment. This is not acceptable. Odylia works hand-in-hand with patient advocacy groups to demystify the drug development process. By working directly with patient groups Odylia can prioritize the patients' needs when developing and advancing therapies towards clinical trials. Using a business model focused on the safety and efficacy of treatments, and not financial profit, Odylia increases drug development for rare diseases by accelerating programs even in small patient populations. These groups can be a part of pharmaceutical development without paying big pharmaceutical prices. Our goal is to impact all rare diseases, affecting 40 million people in the United States, 400 million worldwide by focusing on community involvement, proactive risk management, and an innovative business model. But we can't do it alone. By transforming the existing for-profit model, we can convert rare diseases from life-limiting conditions into treatable or even curable ones, ultimately redefining what is possible. Odylia drives therapeutic advancement through two core initiatives: the Odylia Pipeline and Brydge Solutions. Our internal pipeline includes three gene therapy programs: one that has pre-IND approval and is in late stages of preclinical testing, one in the process of submitting an application for pre-IND approval and one in early stage preclinical testing. To move each program forward, we break down competitive barriers, bringing together a coalition of patient advocacy groups, researchers, industry partners, and funders who play pivotal roles. We measure success through efficient timelines, lower costs, and fewer stalled or terminated programs in the rare disease space because life-changing treatments should not be shelved due to limited financial profit. We take pride in our team's deep expertise in drug development, genuine empathy, and firsthand experience with rare diseases. Our team's depth in scientific and operational strategy enable us to remain agile in the constantly evolving landscape of therapeutic development. Through our Brydge Solutions Program Odylia partners with patient advocacy groups at all stages of therapeutic development to bring our drug development expertise to the broader rare disease community. Odylia utilizes internal knowledge from our pipeline programs to educate and guide our partners through the same process. Working closely with patient groups, we provide direct access to drug development so patient groups don't need to wait for a pharmaceutical company to take an interest in their disease. We help groups focus on prioritizing development of therapies that are safe, effective, and treat the symptom(s) most relevant to the patient community. Our goal is to bring scientific expertise to these groups - the next generation of rare disease drug developers. We empower them to identify and prioritize what matters most to their communities, advance the most promising therapies, and focus limited resources on the science with the greatest potential impact.We streamline the path from early discovery to clinical trials by reducing common inefficiencies.